Kite Pharma Provides Update on KTE-C19 Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Standpoint Research Starts Kite Pharma (KITE) at Buy
August 17, 2015 9:42 AM EDTStandpoint Research initiated coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $100.00.
For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.
Shares of Kite Pharma closed at $58.00 yesterday.
... More